Insight into antidiabetic therapies: a report from the 43rd annual meeting of the European Association for the Study of Diabetes.
Rabasseda
X
X
Prous Science Medical Information Department.
D000682:Amyloid / Q000819:agonists; D001645:Biguanides / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000628:therapy*; D019587:Dietary Supplements; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D006597:Fructose-Bisphosphatase / Q000037:antagonists & inhibitors; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives / Q000627:therapeutic use; D058228:Islet Amyloid Polypeptide; D008517:Phytotherapy; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use
D000682:Amyloid; D001645:Biguanides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D052216:Glucagon-Like Peptide 1; D006597:Fructose-Bisphosphatase